

Table 2. Incidence rate and risk of VTE associated to each AOM versus alendronate (Hazard Ratio) overall and by age in CPRD and BIFAP.

	Alendronate	Other Biphosphonates	Strontium Ranelate	Denosumab	Teriparatide
CPRD					
Number of patients at risk	127121	29007	3045	29	7
VTE treated	1644	365	25	1	0
50-59y	141	33	2	0	0
60-69y	342	73	3	0	0
70-70y	608	144	7	0	0
>=80y	553	115	13	1	0
Incidence rate per 1000 person-years	4.84 (4.61-5.08)	5.08 (4.59-5.63)	5.06 (3.42-7.48)	24.06 (3.39-170.8)	-
50-59y	3.15 (2.67-3.72)	3.60 (2.56-5.06)	6.59 (1.64-26.4)	-	-
60-69y	3.87 (3.48-4.30)	3.87 (3.07-4.87)	4.06 (1.30-12.6)	-	-
70-70y	5.07 (4.69-5.49)	5.75 (4.88-6.77)	5.12 (2.44-10.73)	-	-
>=80y	6.39 (5.88-6.94)	6.13 (5.11-7.37)	5.13 (2.98-8.83)	59.9 (8.16-411.12)	-
Crude HR (95%CI)	Ref.	1.03 (0.92-1.15)	0.94 (0.63-1.39)	4.20 (0.59-29.8)	-
Adjusted HR (95%CI) ^a	Ref.	1.05 (0.94-1.18)	0.90 (0.61-1.34)	3.47 (0.49-24.7)	-
Adjusted HR (95%CI) ^b	Ref.	1.06 (0.94-1.18)	0.90 (0.61-1.34)	3.09 (0.43-22.0)	-
BIFAP					
Number of patients at risk	36182	37594	7978	293	1287
VTE treated	186	175	32	1	7
50-59y	7	17	1	0	0
60-69y	35	35	5	0	2
70-79y	89	82	13	1	3
>=80y	55	41	13	0	2
Incidence rate per 1,000 person-years	2.36(2.04-2.72)	2.21(1.91-2.56)	2.89(2.04-4.09)	5.16(0.73-36.60)	4.67(2.22-9.79)

50-59y	0.42(0.20-0.88)	0.95(0.59-1.53)	0.42(0.06-3.00)	0(-)	0(-)
60-69y	1.44(1.04-2.01)	1.42(1.02-1.98)	1.52(0.63-3.65)	0(-)	6.20(1.55-24.80)
70-79y	3.25(2.64-4.01)	3.07(2.48-3.82)	3.56(2.07-6.13)	19.69(2.77-139.77)	5.00(1.61-15.50)
>=80y	5.21(4.00-6.79)	4.09(3.01-5.55)	7.40(4.30-12.74)	0(-)	4.91(1.23-19.65)
Crude HR (95%CI)	Ref.	0.94(0.76-1.16)	1.22(0.84-1.79)	2.08(0.29-14.86)	1.99(0.93-4.26)
Adjusted HR (95%CI) ^a	Ref.	0.96(0.78-1.18)	1.19(0.82-1.74)	1.77(0.25-12.66)	1.27(0.59-2.71)
Adjusted HR (95%CI) ^b	Ref.	0.96(0.78-1.18)	1.17(0.80-1.71)	1.68(0.23-12.05)	1.19(0.56-2.56)

^aHazard ratio (HR) were adjusted as per protocol by age, sex, history of VTE, cancer, peripheral arterial disease, vein insufficiency or phlebitis, recent fractures (recorded during two months before therapy initiation as a proxy for patients who are bed-bound), and hormone replacement therapy prescribed during the year before therapy initiation, BMI and current smoking as recorded during the year of therapy initiation. VTE: Venous thromboembolism including deep vein thrombosis and pulmonary embolism (Annex I). AOM: anti-osteoporosis medication.

^bHR were adjusted by heparins and oral anticoagulant drugs anytime before AOM therapy initiation additionally to HR^a adjustment.